Biotech Showcase™ 2016
January 11 - 13, 2016
Biotech Showcase™ is an investor and networking conference that provides private and public biotechnology and life sciences companies with an opportunity to present, build their profile, conduct one-to-one meetings, and network with investors and pharmaceutical executives – all during the course of one of the industry's largest annual healthcare investor conferences. Now in its eighth year, BTS 2016 is expected to attract more than 2,100 attendees. The program includes lunch plenary sessions featuring top industry leaders and innovators speaking on industry- and time-relevant topics, as well as presentations from both private and public companies. BTS 2016 takes place January 11-13, 2016, in San Francisco. For more information about EBD Group's BTS conference, visit www.ebdgroup.com/bts/
Actinium Pharmaceuticals, Inc. (ATNM)
Actinium Pharmaceuticals, Inc. (NYSE: ATNM) is a biopharmaceutical company focused on the development of cancer drugs. The company's product candidates are based on its patented technology, which combines the cancer targeting precision of monoclonal antibodies with the power of alpha emitting radioisotopes, the most potent cancer killing agent in existence. Actinium intends to develop its drug pipeline – which includes Iomab-B for use in hematopoietic stem cell transplantation and Actimab-A for the treatment of acute myeloid leukemia – through phase II clinical trials before partnering each product candidate with an appropriate third party for completion of development and commercialization. For more information, visit the company's website at www.actiniumpharma.com.
Athersys, Inc. (ATHX)
Athersys, Inc. (NASDAQ: ATHX) is a clinical-stage biotechnology company developing novel and proprietary best-in-class therapies designed to extend and enhance the quality of human life. The company's focus is on the treatment of medical conditions where there is significant unmet clinical need. It is particularly focused on developing therapies in the regenerative medicine area, and is developing MultiStem, a patented, adult-derived "off-the-shelf" stem cell product platform for multiple disease indications in the areas of neurological, cardiovascular disease, inflammatory and immune disease, as well as other areas. For more information, visit the company's website at www.athersys.com.
BIND Therapeutics, Inc. (BIND)
BIND Therapeutics, Inc. (NASDAQ: BIND) is a clinical-stage nanomedicine company developing a pipeline of ACCURINS®, its novel targeted therapeutics designed to increase the concentration and duration of therapeutic payloads at disease sites while reducing exposure to healthy tissue. The company is leveraging its Medicinal Nanoengineering® platform to develop its pipeline of ACCURINS targeting hematological and solid tumors, and has a number of strategic collaborations with biopharmaceutical companies to develop ACCURINS in areas of high unmet need. For more information, visit the company's website at www.bindtherapeutics.com.
BioLineRx Ltd. (BLRX)
Israel-based BioLineRx Ltd. (NASDAQ: BLRX) is a clinical-stage biopharmaceutical company committed to identifying, in-licensing and developing promising therapeutic candidates. The company in-licenses novel compounds primarily from academic institutions and biotech companies based in Israel, develops them through pre-clinical and/or clinical stages, and then partners with pharmaceutical companies for advanced clinical development and/or commercialization. For more information, visit the company's website at www.biolinerx.com.
Biotron Ltd. (BITRF)
Biotron Ltd. (OTC: BITRF) is an Australian biotechnology company based in Sydney. The company develops and commercializes novel small molecule antiviral therapeutics targeting Hepatitis C virus (HCV) and HIV-1. Biotron's lead drug, BIT225 is in clinical development for treatment of both HIV and HCV, as well as the hard to treat HIV/HCV co-infected population. Biotron also has early stage programs targeting other viruses including Dengue and has a research and development program for next generation viroporin inhibitors for its HIV/HCV programs. For more information, visit the company's website at www.biotron.com.au.
Bovie Medical Corp. (BVX)
Bovie Medical Corp. (NYSE: BVX) is a maker of medical devices and supplies. The company is also the developer of J-Plasma, a patented, new plasma-based surgical product that has the potential to be a transformational tool for surgeons. Bovie Medical Corporation came into being with far simpler technology. The company was born in the late 1970s as a manufacturer of disposable penlights for the medical industry and the success of this line prompted the development and manufacture of battery-operated, tubular products, with the same type of assembly manufacturing technologies. For more information, visit the company's website at www.boviemedical.com.
Capricor Therapeutics, Inc. (CAPR)
Capricor Therapeutics, Inc. (NASDAQ: CAPR) is focused on discovering, developing and marketing first-in-class therapeutics for the treatment of diseases. Presently, the company is positioned at the forefront of one of the largest segments of the U.S. healthcare industry: heart disease. Capricor's lead product candidates currently target the prevention and treatment of heart failure and heart attacks, which make up a substantial portion of the estimated total annual costs of heart disease in the U.S. (over $200 billion). For more information, visit the company's website at www.capricor.com.
Cellceutix Corp. (CTIX)
Cellceutix Corp. (OTC: CTIX) has brought together leading figures in the health and science arenas to work toward the goal of developing innovative small molecule therapies for areas of unmet medical need, particularly infectious disease, oncology and dermatology. The officers and advisors of Cellceutix include pioneers in the fields of cancer and genetics, as well as pharmaceutical executives. Their invaluable experiences cover all areas of researching, developing, and marketing ground breaking therapies. For more information, visit the company's website at www.cellceutix.com.
Cyclacel Pharmaceuticals, Inc. (CYCC)
Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC) is a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious diseases. Professor Sir David Lane, a recognized leader in the field of tumor suppressor biology, founded the company in 1996. In 1999, Professor David Glover, a recognized leader in the mechanism of mitosis or cell division, also joined the company. For more information, visit the company's website at www.cyclacel.com.
Cytosorbents Corp. (CTSO)
Cytosorbents Corp. (NASDAQ: CTSO) is a critical care-focused immunotherapy company using blood purification to control severe inflammation with the goal of preventing or treating multiple organ failure in life-threatening illnesses. CytoSorb®, the company's flagship product, is approved in the EU with distribution in 31 countries around the world, among other uses, designed to reduce the "cytokine storm" that could otherwise cause massive inflammation, organ failure and death in common critical illnesses such as sepsis, burn injury, trauma, lung injury, and pancreatitis. CytoSorbents has numerous products under development based upon this unique blood purification technology, protected by 32 issued U.S. patents and multiple applications pending. For more information, visit the company's website at www.cytosorbents.com.
Dipexium Pharmaceuticals, Inc. (DPRX)
Dipexium Pharmaceuticals, Inc. (NASDAQ: DPRX) is a late stage pharmaceutical company focused on developing and selling Locilex (pexiganan cream 0.8%), a potent and broad spectrum topical antibiotic peptide, for the treatment of mild and moderate skin and skin structure infections. The company means to establish Locilex as the standard of care for the treatment of mild infections of diabetic foot ulcers, an indication for which there are currently no products specifically approved by the U.S. Food and Drug Administration. For more information, visit the company's website at www.dipexiumpharmaceuticals.com.
Harvard Apparatus Regenerative Technology (HART)
Harvard Apparatus Regenerative Technology (NASDAQ: HART) makes bioengineered organs for life-threatening conditions. Its technology platform focuses on the function restoration of the airways and esophagus. The company's HART-Trachea technology has been used in several human trachea transplants to date and approved under compassionate use exemptions. However, none of its products are yet approved by a government regulatory authority for marketing. For more information, visit the company's website at www.harvardapparatus.com.
Histogenics Corp. (HSGX)
Histogenics Corp. (NASDAQ: HSGX) is a regenerative medicine company focused on developing and commercializing products in the musculoskeletal segment of the marketplace. Histogenics' regenerative medicine platform combines expertise in cell processing, scaffolding, tissue engineering, bioadhesives and growth factors to provide solutions that can be utilized individually or in concert to treat musculoskeletal-related conditions. Histogenics' first investigational product candidate, NeoCart, leverages its platform to provide an innovative treatment in the orthopedic space, specifically cartilage damage in the knee. For more information, visit the company's website at www.histogenics.com.
InVivo Therapeutics Holdings Corp. (NVIV)
InVivo Therapeutics Holdings Corp. (NASDAQ: NVIV) is on a quest to redefine the life of the spinal cord injury patient. Armed with cutting-edge technology and MIT science, experienced business and medical professionals at InVivo Therapeutics are pushing the boundaries of spinal cord injury research. As the recognized leader in the SCI field, the company has a singular focus: improving quality-of-life — and redefining life — for the SCI patients it serves. For more information, visit the company's website at www.invivotherapeutics.com.
Fate Therapeutics, Inc. (FATE)
Fate Therapeutics, Inc. (NASDAQ: FATE) is a clinical‑stage biopharmaceutical company engaged in the development of programmed cellular therapeutics for the treatment of severe, life‑threatening diseases. The company is primarily focused on developing programmed hematopoietic cellular candidates as therapeutic entities for the treatment of hematologic malignancies, rare genetic disorders, and diseases resulting from the dysregulation of the immune system. Fate has built a novel platform to program the function and fate of cells ex vivo using pharmacologic modulators, such as small molecules. For more information, visit the company's website at www.fatetherapeutics.com.
Kitov Pharmaceuticals Holdings Ltd. (KTOV)
Kitov Pharmaceuticals Holdings Ltd. (NASDAQ: KTOV) is a biopharmaceutical company focused on the development of therapeutic candidates for the simultaneous treatment of various clinical conditions. Kitov focuses on developing combinations of existing drugs in advanced stages of development. Kitov's lead drug, KIT-302, is formulated for the simultaneous treatment of two clinical conditions – pain caused by osteoarthritis (OA) and hypertension (high blood pressure), which can be pre-existing or caused by the treatment for OA. KIT-302 is based on celecoxib, the active ingredient of a known and approved-for-use drug designed primarily to relieve pain caused by OA, and the generic drug amlodipine besylate. For more information, visit the company's website at www.kitovpharma.com.
Midatech Pharma (MTP)
Midatech Pharma (NASDAQ: MTP) is a nanomedicine company focused on advancing a pipeline of novel clinical and pre-clinical product candidates based on its proprietary drug conjugate and sustained release delivery platforms with a clear focus on the key therapeutic areas of diabetes, cancer and neuroscience/ophthalmology. Midatech's strategy is to develop its products in-house in rare cancers and with partners in other indications, and to accelerate growth of its business through the strategic acquisition of complementary products and technologies. For more information, visit the company's website at www.midatechgroup.com.
Mymetics Corp. (MYMX)
Mymetics Corp. (OTC: MYMX) is a Switzerland-based biotechnology company focused on the development of next-generation preventative vaccines for infectious diseases. The company's vaccines are designed to induce protection against early transmission and infection. They focus on the mucosal immune response as a first line of defense, which, for some pathogens, may be essential for the development of an effective prophylactic vaccine. Mymetics currently has five vaccines in its pipeline for HIV-1/AIDS, intra-nasal influenza, malaria, herpes simplex virus and the RSV vaccine. For more information, visit the company's website at www.mymetics.com.
Neurometrix, Inc. (NURO)
Neurometrix, Inc. (NASDAQ: NURO) is an innovative health-care company that develops wearable medical technology and point-of-care test that help patients and physicians better manage chronic pain, nerve diseases, and sleep disorders. The company's expertise in biomedical engineering has been refined over nearly two decades of designing, building and marketing medical devices that stimulate nerves and analyze nerve response for diagnostic and therapeutic purposes. NeuroMetrix created the market for point-of-care nerve testing and was first to market with sophisticated, wearable technology for management of chronic pain. For more information, visit the company's website at www.neurometrix.com.
OncoSec Medical Incorporated (ONCS)
Established in 2011, OncoSec Medical Incorporated (NASDAQ: ONCS) is a San Diego-based biotechnology company pioneering new technologies to stimulate the body's immune system to target and attack cancer. Through its proprietary technology, the company means to deliver safer and more effective cancer treatments that can provide long-term benefits for patients. OncoSec's investigational platform, ImmunoPulse, is designed to enhance local delivery and uptake of DNA-based therapeutics directly into tumors. For more information, visit the company's website at www.oncosec.com.
Oxford BioMedica plc (OXBDF)
At Oxford BioMedica plc (OTC: OXBDF), the mission is to build a valuable, profitable biopharmaceutical company through the successful development and commercialization of breakthrough gene and cell-based medicines that improve the lives of patients. The company believes that gene therapy will become a mainstay of patient therapy in the future, and its long-term goal is to become a standalone, self-financing gene and cell therapy medical business with the capabilities and capacity to take its products through to market. For more information, visit the company's website at www.oxfordbiomedica.co.uk.
Parnell Pharmaceuticals Holdings Ltd. (PARN)
Parnell Pharmaceuticals Holdings Ltd. (NASDAQ: PARN) is a fully integrated pharmaceutical company focused on developing, manufacturing and commercializing innovative animal health solutions. Parnell currently markets five products for companion animals and production animals in 14 countries and augments its pharmaceutical products with proprietary software platforms – FETCH and mySYNCH. These innovative technology solutions are designed to enhance the quality of life and/or performance of animals, while driving customers' operational efficiency and profitability. For more information, visit the company's website at www.parnell.com.
Pulmatrix, Inc. (PULM)
Pulmatrix, Inc. (NASDAQ: PULM) is developing innovative inhaled therapies to address serious pulmonary disease using its clinically validated, proprietary iSPERSE technology. Leveraging the unique capabilities of iSPERSE to dramatically advance inhalation technology, the company means to create new therapies to improve patient outcomes. Pulmatrix's pipeline of inhaled therapies represents innovative, first-in-class products. This proprietary pipeline of novel, therapies for rare, orphan diseases is led by PUR1900, an inhaled anti-infective to treat fungal infections in cystic fibrosis or immune compromised patients. For more information, visit the company's website at www.pulmatrix.com.
Q BioMed, Inc. (QBIO)
Q BioMed, Inc. (OTC: QBIO) is a biomedical acceleration and development company focused on acquiring companies and biomedical assets. Q BioMed is dedicated to providing these target companies and assets, strategic resources, developmental support, and expansion capital to ensure they meet their developmental potential enabling them to provide products to patients in need. The company is assessing multiple biomedical assets in various areas of healthcare and drug development, and is actively pursuing a pipeline of therapeutics, diagnostics and orphan drug candidates with potential to provide a robust technology platform from which to build significant value. For more information, visit the company's website at www.qbiomed.com.
RepliCel Life Sciences, Inc. (REPCF)
RepliCel Life Sciences, Inc. (OTC: REPCF) is a regenerative medicine company focused on developing autologous cell therapies that address conditions caused by a deficit of healthy cells required for normal healing and function. The company's product pipeline is comprised of two ongoing clinical trials (RCT-01 for tendon repair and RCS-01 for skin rejuvenation) as well as its RCH-01 hair restoration product under exclusive license by the Shiseido Company for certain Asian countries. For more information, visit the company's website at www.replicel.com.
RespireRx Pharmaceuticals, Inc. (CORX)
RespireRx Pharmaceuticals, Inc. (OTC: CORX), formerly Cortex Pharmaceuticals, Inc., has multiple drug development programs targeted toward the treatment of brain-related breathing disorders, such as obstructive or central sleep apnea and drug-induced respiratory depression – areas where current treatment options are limited or inadequate. The company's product candidate portfolio includes two clinical stage compounds: dronabinol, which is being developed for obstructive sleep apnea; and CX1739, which is being developed for multiple respiratory indications, including central sleep apnea and drug-induced respiratory depression. For more information, visit the company's website at www.respirerx.com.
Rexahn Pharmaceuticals, Inc. (RNN)
Rexahn Pharmaceuticals, Inc. (NYSE: RNN) is a clinical-stage biopharmaceutical company dedicated to the development of novel, best-in-class therapeutics for the treatment of cancer. The company's product candidates work by targeting and neutralizing specific proteins believed to be involved in the complex biological cascade that leads to cancer cell growth. Rexahn's development pipeline includes three anti-cancer compounds currently in clinical development – including Supinoxin™, RX-3117 and Archexin® – as well as a novel nanopolymer-based drug delivery platform technology that may increase the bio-availability of FDA-approved chemotherapies. For more information, visit the company's website at www.rexahn.com.
Rock Creek Pharmaceuticals, Inc. (RCPI)
Rock Creek Pharmaceuticals, Inc. (NASDAQ: RCPI) is an emerging drug development company focused on the discovery, development and commercialization of new drugs, formulations, and compounds that provide therapies for chronic inflammatory disease and neurologic disorders. Rock Creek's lead compound, Anatabine Citrate, is a small molecule, cholinergic agonist which exhibits anti-inflammatory pharmacological characteristics, distinct from other anti-inflammatory drugs available such as biologics, steroids and non-steroidal anti-inflammatories. The company has sponsored extensive pre-clinical (in vitro and in vivo) studies resulting in peer reviewed and published scientific journal articles, covering models of multiple sclerosis, Alzheimer's disease, and auto-immune thyroiditis. For more information, visit the company's website at www.rockcreekpharmaceuticals.com.
RXi Pharmaceuticals Corp. (RXII)
RXi Pharmaceuticals Corp. (NASDAQ: RXII) is a biotechnology company focused on discovering and developing innovative therapeutics, primarily in the areas of dermatology and ophthalmology, addressing high-unmet medical needs. The company's discovery and clinical development programs are based on siRNA technology as well as immunotherapy agents. These compounds include, but are not limited to, RXi's proprietary, self-delivering RNAi (sd-rxRNA) compounds for the treatment of dermal and retinal scarring. RXi's robust pipeline, coupled with an extensive patent portfolio, provides for product and business development opportunities across a broad spectrum. For more information, visit the company's website at www.rxipharma.com.
SciClone Pharmaceuticals (SCLN)
SciClone Pharmaceuticals (NASDAQ: SCLN) is a specialty pharmaceutical company with a substantial commercial business in China and a product portfolio spanning major therapeutic markets including oncology, infectious diseases and cardiovascular disorders. The company's proprietary lead product, ZADAXIN® (thymalfasin), is approved in over 30 countries and may be used for the treatment of hepatitis B (HBV), hepatitis C (HCV), and certain cancers, and as a vaccine adjuvant, according to local regulatory approvals. SciClone has successfully in-licensed and commercialized products, including DC Bead®, a novel treatment for liver cancer. For more information, visit the company's website at www.sciclone.com.
Sorrento Therapeutics, Inc. (SRNE)
Sorrento Therapeutics, Inc. (NASDAQ: SRNE) is a clinical-stage biopharmaceutical company developing new treatments for cancer, as well as associated pain, inflammation and immune diseases. The company recently licensed multiple late-stage biosimilar and biobetter antibodies for oncology and inflammation diseases in the U.S., European and Japanese markets. Sorrento's lead product is resiniferatoxin, a non-opiate TRPV1 agonist currently being developed as a treatment for terminal cancer patients suffering from intractable pain. For more information, visit the company's website at www.sorrentotherapeutics.com.
Strongbridge Biopharma plc (SBBP)
Strongbridge Biopharma plc (NASDAQ: SBBP) is a biopharmaceutical company focused on rare endocrine disorders and other rare diseases. The company is committed to the development, in-licensing, acquisition and eventual commercialization of complementary product candidates across multiple franchises. Its primary focus has been to build its franchise around rare endocrine disorders, which includes product candidates for the treatment of endogenous Cushing's syndrome and acromegaly, two rare diseases with a high unmet need for innovative treatment options. For more information, visit the company's website at www.strongbridgebio.com.
Synthetic Biologics, Inc. (SYN)
Synthetic Biologics, Inc. (NYSE: SYN) is a clinical stage company developing therapeutics to protect the gut microbiome while targeting pathogen-specific diseases. One of the company's lead candidates in phase 2 development is SYN-004 which is designed to protect the gut microbiome from the effects of certain commonly used intravenous (IV) beta-lactam antibiotics for the prevention of C. difficile infection and antibiotic-associated diarrhea (AAD). For more information, visit the company's website at www.syntheticbiologics.com.
TapImmune Inc. (TPIV)
TapImmune Inc. (OTC: TPIV) is an immunotherapy company specializing in the development of innovative technologies for the treatment of cancer and infectious diseases. The company's peptide or nucleic acid-based immunotherapeutics comprise one or more naturally processed epitopes designed to comprehensively stimulate patients' T-cells while restoring or further augmenting antigen presentation. TapImmune's technologies are suitable for use as stand-alone medications, as well as in combination with current treatment modalities. For more information, visit the company's website at www.tapimmune.com.
TiGenix NV (TIG)
TiGenix NV (NYSE: TIG) is a leading European cell therapy company with an advanced clinical stage pipeline of adult stem cell programs, and a commercialized product. The stem cell programs are based on proprietary validated platforms of allogeneic expanded stem cells targeting autoimmune, inflammatory and heart diseases. Built on solid pre-clinical and CMC packages, they are being developed in close consultation with the European Medicines Agency. For more information, visit the company's website at www.tigenix.com.